Table 2 CircRNAs as diagnostic and prognostic biomarkers in GC
From: Biogenesis, functions and clinical significance of circRNAs in gastric cancer
Name | Dysregulation | Function | Sensitivity | Specificity | Cut-off value (ΔCt) | AUC | Clinicopathological association | Ref. |
|---|---|---|---|---|---|---|---|---|
circPVT1 | up-regulated | Independent prognostic indicator; | – | – | – | 0.605 | Tumor stage and overall survival time | [75] |
hsa_circ_0014717 | downregulated | Diagnostic biomarker | 59.38% | 81.25% | 12.14 | 0.696 | Tumor stage, distal metastasis, CEA, and CA19–9 | [92] |
circLARP4 | downregulated | Independent prognostic indicator | 67.4% | 67.6% | 20.37 | 0.64 | Tumor size and lymphatic metastasis | [96] |
circ-KIAA1244 | downregulated | Independent prognostic indicator | 77.42% | 68.00% | 1.443 | 0.748 | TNM stage, lymphatic metastasis and overall survival time | [99] |
hsa_circ_0000467 | up-regulated | Independent prognostic factor; potential target | 70.5% | 64.8% | – | 0.799 | Lymphatic invasion, and TNM stage | [100] |
hsa_circ_0000190 | downregulated | Diagnosis biomarker | 72.1% | 68.3% | 6.83 | 0.75 | Tumor size, lymphatic metastasis, distal metastasis, TNM stage and CA19–9 | [101] |
hsa_circ_002059 | downregulated | Diagnosis biomarker | 81% | 62% | 12.9 | 0.73 | TNM stage, distal metastasis, gender and age | [102] |
hsa_circ_0000181 | downregulated | Diagnosis biomarker | 20.6% | 99% | 7.27 | 0.582 | Differentiation and CEA (plasma) | [103] |
85.2% | 53.9% | 9.4 | 0.756 | Tumor diameter, lymphatic metastasis, distal metastasis and CA19–9 (tissue) | ||||
hsa_circ_0000096 | downregulated | Diagnosis biomarker | – | – | 12.9 | 0.82 | Gender, invasion and TNM stage | [104] |
hsa_circ_0003159 | downregulated | Diagnosis biomarker | 85.2% | 56.5% | 12.31 | 0.75 | Gender, TNM stage and distal metastasis | [105] |
circPSMC3 | downregulated | Diagnosis and prognosis biomarker | 85.85% | 95.24% | 9.965 | 0.933 | TNM stage and lymphatic metastasis | [95] |
hsa_circ_0000745 | downregulated | Diagnosis biomarker | 85.5% | 45% | – | 0.683 | TNM stage (plasma) and tumor differentiation (tissue) | [106] |
hsa_circ_0006633 | downregulated | Diagnosis biomarker | 60% | 81% | 8.17 | 0.741 | Distal metastasis and CEA | [107] |
hsa_circ_0001649 | downregulated | Independent prognostic indicator and diagnosis biomarker | 71.1% | 81.6% | 0.227 | 0.834 | Tumor differentiation | [108] |
hsa_circ_0001895 | downregulated | Prognosis biomarker | 67.8% | 85.7% | 9.53 | 0.792 | Cell differentiation, Borrmann type, and CEA | [109] |
has_circ_0074362 | downregulated | Diagnosis biomarker | 84.3% | 36.2% | 12.17 | 0.63 | Lymphatic metastasis and CA19–9 | [110] |
hsa_circ_102958 | up-regulated | Diagnosis biomarker | 61% | 86% | – | 0.74 | TNM stage | [111] |
has_circ_0066444 | up-regulated | Diagnosis biomarker | 70.75% | 68.87% | – | 0.733 | Lymph metastasis | [112] |